Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

BioDelivery Sciences International, Inc. company was founded in 1997 and is based in Raleigh, North Carolina. BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB.BioDelivery Sciences Company's products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease.

ReGen Therapeutics did. Its main product is Colostrinin, a polypeptide derived from ovine and bovine colostrum (the first milk produced after the birth of an offspring). The company developed a nutraceutical version of the product that its licensee Metagenics launched in the US under the name CogniSure in 2007. ReGen continues development of a pharmaceutical preparation, as well as a veterinary nutraceutical version for pets. In addition to Colostrinin, ReGen is developing existing insomnia drug Zolpidem as a treatment for head trauma victims. The company's Guildford Clinical Pharmacology subsidiary is a UK-based contract research organization.

Ironwood Pharmaceuticals (formerly Microbia) is a drug developer that is busy testing the gastrointestinal drug candidates in its pipeline. The company is developing lead drug candidate linaclotide, which is undergoing trials in partnership with Forest Laboratories and other co-developers for the treatment of irritable bowel syndrome, abdominal pain, and chronic constipation. The company's Microbia biotechnology subsidiary harnesses microbes to produce specialty chemicals from renewable resources with applications the agriculture, chemical, and pharmaceutical industries. Ironwood Pharmaceuticals made a move to go public when it filed for an IPO in 2009.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The company's products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis.

New Energy Technologies, Inc. was founded in 1998 and is based in Burtonsville, Maryland. New Energy Technologies, Inc., through its subsidiaries, engages in the identification, acquisition, development, and commercialization of alternative energy technologies. It focuses on the development of MotionPower, a technology for capturing the kinetic energy of moving vehicles in order to use this captured energy to generate electricity; and SolarWindow, a technology that enables transparent glass windows to generate electricity by coating their glass surfaces with small solar cells. The company was formerly known as Octillion Corp. and changed its name to New Energy Technologies, Inc. in January 2009.

Gemini Pharmaceuticals' private label products are formulated to be as effective as their name-brand twins. The company makes prescription and OTC pharmaceuticals and nutritional supplements, including acetaminophen, vitamin B-12, and herbal enhancers. Its pharmaceutical offerings include cough and cold medications, pain relievers, and sleeping aids. Its supplement product line starts with such basics as vitamins and minerals, and then includes what it calls "specialty products" such as energy boosters and weight loss supplements. Gemini Pharmaceuticals also makes pet care supplements such as joint support and allergy relief and prescription prenatal vitamins and other custom formulations.

Pfizer decided to put a Cork in it, the pharmaceutical giant made Ireland one of the world's largest manufacturers and exporters of pharmaceuticals. Pfizer Ireland Pharmaceuticals is part of the Pfizer Global Manufacturing division. Parent company Pfizer began operating in Ireland in 1969 with a citric acid manufacturing plant and now operates about a dozen Irish plants. Its manufacturing facilities are involved in the development, formulation, and bulk manufacture of human pharmaceuticals (especially cardiovascular drugs) and animal health care products, as well as sterile pharmaceutical products and active pharmaceutical ingredients.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.